Small Intestinal Bacterial Overgrowth (SIBO) in Pancreatic Adenocarcinoma (PDAC)
A Prospective Study to Assess the Prevalence of Small Intestinal Bacterial Overgrowth (SIBO) in Pancreatic Adenocarcinoma (PDAC) Patients With Weight Loss
Cedars-Sinai Medical Center
100 participants
Apr 14, 2025
OBSERVATIONAL
Conditions
Summary
The purpose of this study is to prospectively analyze the prevalence of SIBO in patients with Pancreatic adenocarcinoma (PDAC) and understand its association with weight loss and pancreatic resection status. Each patient will be tested for SIBO using Lactulose Hydrogen Breath Test. 100 patients with diagnosed pancreatic adenocarcinoma and clinically diagnosed weight loss will be enrolled in this study.
Eligibility
Inclusion Criteria6
- Men, Women, and all genders
- Individuals 18 years old or older are included.
- Patients of the study investigators and team members
- Diagnosis of pancreatic ductal adenocarcinoma
- All subjects must consent to this study
- Clinically diagnosed weight loss
Exclusion Criteria4
- Minors
- Pregnant Women
- Any records flagged "break the glass" or "research opt out."
- Patients who have received treatment for SIBO in the past 3 months
Interested in this trial?
Get notified about updates and connect with the research team.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06988150